Morgan Stanley analyst Judah Frommer has maintained their bullish stance on KYMR stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer has given his Buy rating due to a combination of factors including the promising progress of Kymera Therapeutics’ KT-621 program. The company is advancing with its Phase 1b BroADen study, which is a significant step in establishing a profile similar to that of dupilumab. The upcoming data release in the fourth quarter of 2025 is anticipated to be a critical milestone for de-risking the program, which could enhance investor confidence.
Furthermore, Kymera is well-positioned financially, ending the second quarter of 2025 with approximately $1 billion in cash, ensuring operational runway into the second half of 2028. The initiation of Phase 2b trials for atopic dermatitis and asthma is on track, with additional dose levels being evaluated, indicating a strategic approach to clinical development. These factors collectively contribute to the positive outlook and justify the Buy rating by Frommer.
According to TipRanks, Frommer is an analyst with an average return of -7.3% and a 42.45% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, RegenXBio, and PTC Therapeutics.